Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
137.8 USD | -0.87% | +3.94% | +4.55% |
Evolution of the average Target Price on Neurocrine Biosciences, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Neurocrine Biosciences, Inc.
Wells Fargo Securities | |
Morgan Stanley | |
JPMorgan Chase | |
Oppenheimer | |
UBS | |
Deutsche Bank Securities | |
Citigroup | |
Mizuho Securities | |
Wedbush | |
Goldman Sachs | |
Barclays | |
RBC Capital Markets | |
Stifel Nicolaus | |
Piper Sandler | |
Raymond James | |
Jefferies & Co. | |
HC Wainwright | |
Canaccord Genuity | |
BMO Capital | |
Baird | |
Guggenheim | |
Evercore ISI | |
SVB Securities LLC | |
Royal Bank of Canada | |
Cantor Fitzgerald | |
J.P. Morgan Chase | |
SVB Leerink | |
Credit Suisse |
EPS Revisions
- Stock Market
- Equities
- NBIX Stock
- Consensus Neurocrine Biosciences, Inc.